Inovio Pharmaceuticals, Inc. is a clinical‐stage biotechnology company that develops DNA and messenger RNA (mRNA) immunotherapies and vaccines designed to prevent and treat a range of infectious diseases and cancers. The company’s proprietary platform leverages synthetic DNA constructs delivered directly into cells via its CELLECTRA® electroporation technology, enabling efficient uptake and robust immune system activation. Inovio’s research focuses on both prophylactic vaccines against emerging pathogens and therapeutic vaccines aimed at stimulating targeted T‐cell responses against diseased cells.
The company’s pipeline encompasses vaccine candidates for a variety of infectious threats including human papillomavirus (HPV), COVID-19, Middle East Respiratory Syndrome (MERS), Ebola, Zika, Lassa fever and influenza. Inovio’s lead infectious disease program, INO-4800 for COVID-19, has advanced through clinical development in multiple geographies. In the oncology arena, programs such as INO-5401 for glioblastoma and INO-3112 for HPV-related head and neck cancers aim to harness the body’s immune defenses to attack tumors. Inovio collaborates with pharmaceutical and governmental partners to support clinical trials, accelerate development and facilitate potential licensure across diverse regions.
Founded in 1983 and headquartered in Plymouth Meeting, Pennsylvania, Inovio maintains a global footprint with research and development activities in North America, Europe and Asia. Its technology platform has evolved through decades of optimization, with more than 3,000 volunteers having received its DNA medicines in clinical studies worldwide. The company complements its in‐house expertise by forming strategic alliances with leading biopharma companies, non-profit foundations and global health agencies to address urgent public health needs and advance novel immunotherapies toward regulatory approval.
Under the leadership of President and Chief Executive Officer J. Joseph Kim, Inovio continues to expand its manufacturing capabilities, strengthen its intellectual property portfolio and explore next-generation delivery technologies. The executive team’s vision emphasizes agility in responding to emerging disease outbreaks and a commitment to translate cutting-edge science into scalable vaccine and immunotherapy solutions. Through its sustained focus on DNA and mRNA innovation, Inovio aims to deliver safe and effective products that can be rapidly deployed worldwide.
AI Generated. May Contain Errors.
Free INO Stock Alerts